madman
Super Moderator
Drug development continues to focus on the challenge of treating acne effectively and safely. Inflammation is a backdrop to the commonly cited elements of the pathophysiology of acne: Propionibacterium acnes proliferation, increased sebum production with an increase in circulating androgens, and faulty keratinization. As such, there is increased emphasis on targeting inflammation and its effects. Vehicle innovations are optimizing existing active drugs and creating opportunities to deliver new compounds to the skin. Recently approved sarecycline is the first new chemical entity approved for acne in several years. It might be followed in coming years by other new actives, including clascoterone and cannabidiol (CBD).
PRACTICE POINTS
*Sarecycline is the first new antibiotic approved for acne in several years.
*Tazarotene foam 0.1% was relaunched to the market. The foam formulation attempts to impart moisturizing effects to offset potential irritation.
*Topical minocycline for acne optimizes the therapeutic effects while reducing systemic effects.
*Clascoterone and cannabidiol currently are under investigation for acne treatment.
Conclusion
Drug development continues to focus on the challenge of treating acne effectively and safely. Vehicle innovations are optimizing existing active drugs and creating opportunities to deliver new compounds to the skin. The approval of sarecycline as the first new chemical entity approved for acne in several years may be followed in coming years by other new actives, including clascoterone and CBD.
PRACTICE POINTS
*Sarecycline is the first new antibiotic approved for acne in several years.
*Tazarotene foam 0.1% was relaunched to the market. The foam formulation attempts to impart moisturizing effects to offset potential irritation.
*Topical minocycline for acne optimizes the therapeutic effects while reducing systemic effects.
*Clascoterone and cannabidiol currently are under investigation for acne treatment.
Conclusion
Drug development continues to focus on the challenge of treating acne effectively and safely. Vehicle innovations are optimizing existing active drugs and creating opportunities to deliver new compounds to the skin. The approval of sarecycline as the first new chemical entity approved for acne in several years may be followed in coming years by other new actives, including clascoterone and CBD.
Last edited:
